CARTISTEM Drug Insight and Market Forecast - 2032

CARTISTEM Drug Insight and Market Forecast − 2032

“CARTISTEM Drug Insight and Market Forecast – 2032” report provides comprehensive insights about CARTISTEM for osteoarthritis in the six major markets. A detailed picture of the CARTISTEM for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in this report along with a detailed description of the CARTISTEM for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CARTISTEM market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary

CARTISTEM is an allogeneic umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) used to treat knee cartilage defects in patients with OA (with ICRS grade IV cartilage defect) caused by degeneration or repetitive trauma. ICRS grade is a diagnostic criterion used for grading the severity of cartilage defects. Grade IV is the most severe stage, with no visible cartilage remaining on the defect area.

Medipost is also planning to enter the Japanese market with a two-track strategy. Separately from the recently approved Phase III clinical trial and a Phase II clinical trial to compare the effects of HTO (High Tibial Osteotomy, a procedure to treat bowlegs [genu varum]) with/without CARTISTEM in 50 patients with mild to severe knee OA (K&L Grade 2–4) is ongoing to obtain conditional product approval since the second half of 2020.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the CARTISTEM description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.

Elaborated details on CARTISTEM regulatory milestones and other development activities have been provided in this report.

The report also highlights the CARTISTEM research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.

The report also covers the patents information with expiry timeline around CARTISTEM.

The report contains forecasted sales of CARTISTEM for osteoarthritis till 2032.

Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.

The report also features the SWOT analysis with analyst views for CARTISTEM in osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CARTISTEM Analytical Perspective by DelveInsight

In-depth CARTISTEM Market Assessment

This report provides a detailed market assessment of CARTISTEM for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

CARTISTEM Clinical Assessment

The report provides the clinical trials information of CARTISTEM for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CARTISTEM dominance.

Other emerging products for osteoarthritis are expected to give tough market competition to CARTISTEM and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CARTISTEM in osteoarthritis.

Our in-depth analysis of the forecasted sales data of CARTISTEM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CARTISTEM in osteoarthritis.

Key Questions

What is the product type, route of administration and mechanism of action of CARTISTEM?

What is the clinical trial status of the study related to CARTISTEM in osteoarthritis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CARTISTEM development?

What are the key designations that have been granted to CARTISTEM for osteoarthritis?

What is the forecasted market scenario of CARTISTEM for osteoarthritis?

What are the forecasted sales of CARTISTEM in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?

What are the other emerging products available and how are these giving competition to CARTISTEM for osteoarthritis?

Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?